Defence Therapeutics Stock Fundamentals
| DTCFF Stock | USD 0.79 0.08 9.20% |
Defence Therapeutics fundamentals help investors to digest information that contributes to Defence Therapeutics' financial success or failures. It also enables traders to predict the movement of Defence OTC Stock. The fundamental analysis module provides a way to measure Defence Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Defence Therapeutics otc stock.
Defence |
Defence Therapeutics OTC Stock Shares Outstanding Analysis
Defence Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Defence Therapeutics Shares Outstanding | 37.85 M |
Most of Defence Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Defence Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Defence Therapeutics has 37.85 M of shares currently outstending. This is 79.03% lower than that of the Healthcare sector and 64.58% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 93.38% higher than that of the company.
Defence Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Defence Therapeutics's current stock value. Our valuation model uses many indicators to compare Defence Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Defence Therapeutics competition to find correlations between indicators driving Defence Therapeutics's intrinsic value. More Info.Defence Therapeutics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Defence Therapeutics' earnings, one of the primary drivers of an investment's value.Defence Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Defence Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Defence Therapeutics could also be used in its relative valuation, which is a method of valuing Defence Therapeutics by comparing valuation metrics of similar companies.Defence Therapeutics is currently under evaluation in shares outstanding category among its peers.
Defence Fundamentals
| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 | |||
| Current Valuation | 60.32 M | |||
| Shares Outstanding | 37.85 M | |||
| Shares Owned By Insiders | 5.26 % | |||
| Price To Book | 36.71 X | |||
| EBITDA | (7.32 M) | |||
| Net Income | (7.34 M) | |||
| Cash And Equivalents | 506.7 K | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 0.61 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (6.04 M) | |||
| Earnings Per Share | (0.15) X | |||
| Market Capitalization | 143.45 M | |||
| Total Asset | 719.67 K | |||
| Z Score | -33.0 | |||
| Net Asset | 719.67 K |
About Defence Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Defence Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Defence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Defence Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.